Healthcare of Ontario Pension Plan Trust Fund Has $2.81 Million Stock Holdings in Becton, Dickinson and Company $BDX

Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 57.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,884 shares of the medical instruments supplier’s stock after purchasing an additional 6,554 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Becton, Dickinson and Company were worth $2,812,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Dai ichi Life Insurance Company Ltd lifted its stake in Becton, Dickinson and Company by 7.7% in the first quarter. Dai ichi Life Insurance Company Ltd now owns 25,159 shares of the medical instruments supplier’s stock valued at $3,956,000 after buying an additional 1,796 shares during the period. Gabelli Funds LLC grew its position in shares of Becton, Dickinson and Company by 6.1% during the 1st quarter. Gabelli Funds LLC now owns 47,003 shares of the medical instruments supplier’s stock worth $7,390,000 after buying an additional 2,708 shares during the period. Hilltop Holdings Inc. bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $277,000. Morningstar Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 5.3% in the 1st quarter. Morningstar Investment Management LLC now owns 19,364 shares of the medical instruments supplier’s stock valued at $3,045,000 after acquiring an additional 983 shares in the last quarter. Finally, GC Wealth Management RIA LLC lifted its position in shares of Becton, Dickinson and Company by 68.3% during the 1st quarter. GC Wealth Management RIA LLC now owns 2,401 shares of the medical instruments supplier’s stock valued at $378,000 after acquiring an additional 974 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several research analyst reports. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Barclays increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday. They issued a “buy” rating and a $190.00 target price for the company. Finally, Stifel Nicolaus reduced their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus price target of $180.93.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $166.19 on Friday. The stock has a market cap of $45.79 billion, a price-to-earnings ratio of 42.07, a PEG ratio of 11.79 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm’s 50-day simple moving average is $151.85 and its 200 day simple moving average is $163.64.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the company posted $3.35 earnings per share. Becton, Dickinson and Company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,189 shares of company stock worth $765,661 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.